Document is current
Any future updates will be listed below
-
Authors
Solis-Jiménez, Fabio https://orcid.org/0000-0002-5145-0680
Esparza, Ximena Latapi-Ruiz https://orcid.org/0000-0001-6581-8805
Guzman-Solorzano, Hannah Priscila https://orcid.org/0009-0005-7672-4587
Villalobos-Pedroza, Monserrat https://orcid.org/0000-0001-9915-2597
Morales-Villamil, Luis Angel https://orcid.org/0009-0002-4116-2359
Diaz-Herrera, Braiana Angeles https://orcid.org/0009-0000-1046-5184
Hernandez-Pastrana, Sarai https://orcid.org/0009-0001-1809-5007
Gopar-Nieto, Rodrigo https://orcid.org/0000-0002-4865-4869
Arias-Sanchez, Eduardo A. https://orcid.org/0000-0002-0520-5465
Marroquín-Donday, Luis Alfonso https://orcid.org/0000-0002-8039-8885
Jiménez-Rodríguez, Gian Manuel https://orcid.org/0000-0003-3275-7115
Sierra-Lara, Daniel https://orcid.org/0000-0003-0308-6973
Araiza-Garaygordobil, Diego https://orcid.org/0000-0003-3185-0051
Arias-Mendoza, Alexandra https://orcid.org/0000-0002-5942-4102
- License Information
-
More Information
Article History
Accepted: 15 September 2025
First Online: 24 September 2025
Declarations
:
: Not applicable.
: Not applicable. This study was retrospective in nature, and informed consent was not required.
: Not applicable. This study did not include any identifiable individual data, and consent for publication was not required.
: DAG reports speaking fees for Abbott, Asofarma, AstraZeneca, Boehringer Ingelheim, Bayer, Lundbeck, Novartis, Novo Nordisk, Silanes, and Servier. Advisory board: Silanes, Servier, Novartis, Novo Nordisk. Research grants: Novartis, Novo Nordisk. RGN reports speaking fees for Novartis and Asofarma. JDSLM reports speaking fees from Bayer, Novartis, and Novo Nordisk. AAM reports speaker fees from Asofarma, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, and Novo Nordisk. The rest of the authors do not report any relevant conflicts of interest.
